Evolent Health stock hits 52-week low at $8.35

Evolent Health Inc . (NYSE:EVH) stock has reached a 52-week low, touching down at $8.35. This latest price level reflects a significant downturn for the company, which has seen its stock value decrease by 63.77% over the past year. Despite generating $2.4 billion in revenue with 10.24% growth over the last twelve months, the company remains unprofitable. According to InvestingPro analysis, the stock appears undervalued at current levels. Investors are closely monitoring the healthcare provider’s performance as it navigates through a challenging market environment, with the hope that the company’s strategic initiatives may eventually steer it back towards a path of growth and recovery. Analysts maintain a bullish outlook, with consensus recommendations strongly favoring the stock, and projections indicate a return to profitability this year. The 52-week low serves as a critical indicator for shareholders and potential investors, marking the lowest price point at which the stock has traded during the last year and setting a new benchmark for the company’s $972 million market valuation. Get deeper insights and access to comprehensive analysis with InvestingPro, which offers exclusive ProTips and detailed financial metrics for informed investment decisions.

In other recent news, Evolent Health Inc. reported its first-quarter 2025 financial results, revealing a mixed performance. The company’s revenue reached $483.6 million, surpassing the forecast of $460.58 million, indicating strong sales performance. However, earnings per share (EPS) fell short, coming in at $0.06 compared to the expected $0.08. Despite the EPS miss, Evolent Health launched new oncology solutions and expanded its market reach, maintaining an optimistic outlook for 2025 with revenue guidance between $2.06 billion and $2.11 billion. The company anticipates a second-quarter revenue range of $440 million to $470 million and adjusted EBITDA guidance of $33 million to $40 million. In strategic moves, Evolent Health announced the acquisition of oncology navigation assets from a joint venture to accelerate its oncology strategy. These developments reflect Evolent Health’s ongoing efforts to expand its market presence and enhance its specialty condition management offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.